Financial Results for FY2018 Third Quarter. February 1, 2019

Transcription

1 Financial Results for FY2018 Third February 1, 2019

2 (Cautionary Statement) Statements made in this material with respect to Sumitomo Chemical s current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management s assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical s markets; demand for, and competitive pricing pressure on, Sumitomo Chemical s products in the marketplace; Sumitomo Chemical s ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

3 Contents 2 Financial Results for FY2018 Third Financial Summary 4 Sales revenue by Business segment 5 Core Operating Income by Business segment 6 Segment Analysis 7 Breakdown of Non-recurring Items 12 Consolidated Balance Sheets 13 Consolidated Statements of Cash Flows 14 (Reference: Segment Information) Sales revenue by Business segment (ly) Core Operating Income by Business segment (ly) Major Group Companies

4 Financial Results for FY2018 Third

5 Financial Summary 4 Unit; billions of yen FY2018 Difference Ratio Sales revenue 1, , % Core operating income % (Equity in earnings) (40.0) (32.4) (-7.6) - Non-recurring items Operating income % Finance income/expenses (Gain/loss on foreign currency transactions) (1.7) (4.8) (3.1) - Income tax expenses Net income attributable to non-controlling interests Net income attributable to owners of the parent % ROE 12.5% 9.3% Exchange rate(yen/$) Naphtha price(yen/kl) 39,900 52,200 Overseas sales revenue ratio 63.6% 64.9%

6 Sales revenue by Business segment 5 FY2018 Difference Ratio Sales Price Variance Shipping Volume Variance Unit; billions of yen Foreign Currency Conversion Variance Petrochemicals & Plastics % Energy & Functional Materials % IT-related Chemicals % Health & Crop Sciences % Pharmaceuticals % Others & Adjustments % Total 1, , % Analysis , ,714.1 Sales Price Volume Foreign Exchange FY2018

7 Core Operating Income by Business segment 6 FY2018 Difference Price Variance Cost Variance Shipping Volume Variance and Other Unit; billions of yen Petrochemicals & Plastics Energy & Functional Materials IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Total Total Analysis Price Cost Volume etc. FY2018

8 Petrochemicals & Plastics - Segment Analysis - 7 Sales revenue Total billion(+80.3 from ) Sales price Rise in market price Volume Increase in shipment of Rabigh products Price Volume FX 2018 Foreign exchange -1.1 Core Operating Income Total 51.8 billion(-18.9 from ) 70.7 ± Price variance 0.0 Cost variance 0.0 Better profit margin on raw materials for MMA and synthetic fibers Decrease in profit margin on petrochemical products and synthetic resins Price Cost Volume 2018 etc. Volume variance etc Periodic plant maintenance in Chiba works and Singapore Decrease in license revenue

9 Energy & Functional Materials - Segment Analysis - 8 Sales revenue Total billion(+26.9 from ) Price Volume FX 2018 Sales price Volume Foreign exchange +0.1 Higher market price for aluminum Increase in shipment of lithium-ion secondary battery separator Increase in shipment of cathode materials Increase in shipment of high purity alumina Core Operating Income Total 20.2 billion(+4.3 from ) +8.3 Price variance Cost variance -3.5 Price Cost Volume 2018 etc. Volume variance etc Increase in shipment of lithium-ion secondary battery separator Increase in shipment of high purity alumina

10 IT-related Chemicals - Segment Analysis - 9 Sales revenue Total billion(+14.3 from ) Sales price Volume Decline in selling price of polarizing film Increase in shipment of polarizing film Price Volume FX 2018 Foreign exchange -0.5 Core Operating Income Total 22.3 billion(+8.7 from ) Price variance Decline in selling price of polarizing film Cost variance +4.5 Rationalization of the use of raw materials Improvement of production yield Price Cost Volume 2018 etc. Volume variance etc Increase in shipment of polarizing film

11 Health & Crop Sciences - Segment Analysis - 10 Sales revenue Total billion(-3.5 from ) Sales price -2.5 Lower market price for feed additive methionine Volume +4.7 Increase in shipment of crop protection chemicals in South America and Asia Price Volume FX 2018 Foreign exchange -5.6 Core Operating Income Total 3.9 billion(-14.7 from ) Price variance -5.0 Cost variance -2.5 Lower market price for feed additive methionine Higher feedstock prices Price Cost Volume 2018 etc. Volume variance etc Equity method investment loss on Nufarm

12 Pharmaceuticals - Segment Analysis - 11 Sales revenue Total billion(-8.6 from ) Sales price -6.5 NHI price revision in Japan Price Volume FX 2018 Volume -1.1 Foreign exchange -1.0 Increase in shipment of Latuda in North America Decrease in shipment of long-listed brands in Japan Core Operating Income Total 59.3 billion(-22.3 from ) -6.5 Price variance -6.5 NHI price revision in Japan Cost variance -9.0 Increase in sales expense in North America Price Cost Volume 2018 etc. Volume variance etc One time gain from divestiture of ciclesonide products in previous fiscal year

13 Breakdown of Non-recurring Items 12 FY2018 Unit; billions of yen Difference Restructuring charges Changes in fair value of contingent consideration Gain on sale of property, plant and equipment Impairment loss Others Non-recurring items

14 Consolidated Balance Sheets 13 Unit; billions of yen 31-Mar Dec-18 Difference 31-Mar Dec-18 Difference Current assets 1, , Liabilities 1, , Cash and cash equivalents Trade and other receivables Trade and other payables Interest-bearing Liabilities Inventories Others Others Equity 1, , Non-current assets 1, , Shareholders' equity Property, plant and equipment Goodwill and Intangible assets Other components of equity Non-controlling interests Others Total 3, , Total 3, , Equity attributable to owners of parent to total assets D/E ratio (times) 30.2% 29.9% -0.3%

15 Consolidated Statements of Cash Flows 14 FY2018 Unit; billions of yen Difference Cash flows from operating activities Cash flows from investing activities Free cash flows Cash flows from financing activities Effect of exchange rate changes on cash and cash equivalents Net change in cash and cash equivalents Cash and cash equivalents at end of period

16 (Reference: Segment Information)

17 Sales revenue by Business segment (ly) 16 FY2018 Unit; billions of yen FY2018 (estimated) 1Q 2Q 3Q 4Q 1Q 2Q 3Q 1st Half 2nd Half Petrochemicals & Plastics Energy & Functional Materials IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Total , ,367.9

18 Core Operating Income by Business segment (ly) 17 FY2018 Unit; billions of yen FY2018 (estimated) 1Q 2Q 3Q 4Q 1Q 2Q 3Q 1st Half 2nd Half Petrochemicals & Plastics Energy & Functional Materials IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Total

19 Major Group Companies 18 Company The Polyolefin Company (Singapore) (millions of USD) Petrochemical Corporation of Singapore (millions of USD) Rabigh Refining and Petrochemical Company Dongwoo Fine-Chem (millions of SAR) (billions of KRW) Valent U.S.A. and Subsidiaries (millions of USD) Sales Revenue FY ,958 2,092 1, , Profit Trends Decreased margins and decreased sales volume due to periodic plant maintenance in the current term. Decreased margins and decreased sales volume due to periodic plant maintenance in the current term. 24,687 32,640 Maintain stable operations. Increased due to higher sales volume and other factors despite lower selling price. Due to shipment timing difference and other factors.